Neos Therapeutics Inc (NASDAQ:NEOS) CEO Gerald W. Mclaughlin bought 7,403 shares of the company’s stock in a transaction that occurred on Tuesday, December 4th. The stock was acquired at an average cost of $2.04 per share, for a total transaction of $15,102.12. Following the acquisition, the chief executive officer now directly owns 7,403 shares of the company’s stock, valued at $15,102.12. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink.
NASDAQ NEOS traded down $0.03 during trading hours on Friday, hitting $2.00. The company had a trading volume of 449,956 shares, compared to its average volume of 539,411. Neos Therapeutics Inc has a 1-year low of $1.65 and a 1-year high of $11.69. The company has a market capitalization of $60.24 million, a PE ratio of -0.75 and a beta of 0.34.
Neos Therapeutics (NASDAQ:NEOS) last released its quarterly earnings data on Friday, November 9th. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.03). Neos Therapeutics had a negative net margin of 133.46% and a negative return on equity of 586.25%. The company had revenue of $12.50 million during the quarter, compared to analyst estimates of $14.80 million. As a group, sell-side analysts anticipate that Neos Therapeutics Inc will post -1.71 earnings per share for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in NEOS. Millennium Management LLC acquired a new position in Neos Therapeutics in the first quarter valued at $519,000. Allianz Asset Management GmbH acquired a new position in Neos Therapeutics in the first quarter valued at $161,000. Trexquant Investment LP acquired a new stake in shares of Neos Therapeutics during the second quarter worth about $131,000. Canada Pension Plan Investment Board acquired a new stake in shares of Neos Therapeutics during the second quarter worth about $469,000. Finally, Schwab Charles Investment Management Inc. boosted its stake in shares of Neos Therapeutics by 28.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 56,200 shares of the company’s stock worth $352,000 after buying an additional 12,500 shares during the period. Institutional investors own 45.12% of the company’s stock.
NEOS has been the topic of several recent analyst reports. Zacks Investment Research raised Neos Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 11th. ValuEngine upgraded shares of Neos Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, September 18th. Cantor Fitzgerald restated a “buy” rating and issued a $20.00 price objective on shares of Neos Therapeutics in a research note on Friday, November 9th. JMP Securities decreased their price objective on shares of Neos Therapeutics from $22.00 to $10.00 and set a “market outperform” rating for the company in a research note on Monday, November 12th. Finally, Wells Fargo & Co decreased their price objective on shares of Neos Therapeutics from $11.00 to $6.00 and set an “outperform” rating for the company in a research note on Wednesday, November 14th. One analyst has rated the stock with a sell rating, three have issued a hold rating and three have issued a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $12.00.
TRADEMARK VIOLATION WARNING: This report was originally reported by Equities Focus and is owned by of Equities Focus. If you are accessing this report on another website, it was copied illegally and republished in violation of United States & international trademark & copyright legislation. The original version of this report can be viewed at https://www.equitiesfocus.com/2018/12/08/gerald-w-mclaughlin-buys-7403-shares-of-neos-therapeutics-inc-neos-stock.html.
About Neos Therapeutics
Neos Therapeutics, Inc, a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its product candidates are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms.
Featured Story: What Is An Exchange-Traded Fund (ETF)?
Receive News & Ratings for Neos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.